Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®). (20th May 2015)
- Record Type:
- Journal Article
- Title:
- Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®). (20th May 2015)
- Main Title:
- Comparison of the pharmacokinetics of an oral extended‐release capsule formulation of carbidopa‐levodopa (IPX066) with immediate‐release carbidopa‐levodopa (Sinemet®), sustained‐release carbidopa‐levodopa (Sinemet® CR), and carbidopa‐levodopa‐entacapone (Stalevo®)
- Authors:
- Hsu, Ann
Yao, Hsuan‐Ming
Gupta, Suneel
Modi, Nishit B. - Abstract:
- <abstract abstract-type="main" xml:lang="en"> <title>Abstract</title> <sec id="jcph514-sec-0001" sec-type="section"> <p>IPX066 (extended‐release carbidopa‐levodopa [ER CD‐LD]) is an oral extended‐release capsule formulation of carbidopa and levodopa. The single‐dose pharmacokinetics of ER CD‐LD (as 2 capsules; total dose, 97.5 mg‐390 mg CD‐LD) versus immediate‐release (IR) CD‐LD (25 mg‐100 mg), sustained‐release (CR) CD‐LD (25 mg‐100 mg), and CD‐LD‐entacapone (25 mg‐100 mg‐200 mg) was evaluated in healthy subjects. Following IR dosing, LD reached peak concentrations (C<sub>max</sub>) at 1 hour; LD concentrations then decreased rapidly and were less than 10% of peak by 5 hours. With CR CD‐LD and CD‐LD‐entacapone, LD C<sub>max</sub> occurred at 1.5 hours, and concentrations were less than 10% of peak by 6.3 and 7.5 hours, respectively. The initial increase in LD concentration was similar between ER CD‐LD and IR CD‐LD and faster than for CR CD‐LD and CD‐LD‐entacapone. LD concentrations from ER CD‐LD were sustained for approximately 5 hours and did not decrease to 10% of peak until 10.1 hours. Dose‐normalized LD C<sub>max</sub> values for ER CD‐LD were significantly lower (<italic>P</italic>< .05) than for the other CD‐LD products. Bioavailability of LD from ER CD‐LD was 83.5%, 78.3%, and 58.8% relative to IR CD‐LD, CR CD‐LD, and CD‐LD‐entacapone, respectively.</p> </sec> </abstract>
- Is Part Of:
- Journal of clinical pharmacology. Volume 55:Number 9(2015:Sep.)
- Journal:
- Journal of clinical pharmacology
- Issue:
- Volume 55:Number 9(2015:Sep.)
- Issue Display:
- Volume 55, Issue 9 (2015)
- Year:
- 2015
- Volume:
- 55
- Issue:
- 9
- Issue Sort Value:
- 2015-0055-0009-0000
- Page Start:
- 995
- Page End:
- 1003
- Publication Date:
- 2015-05-20
- Subjects:
- Pharmacology -- Periodicals
Pharmacology -- Periodicals
Pharmacology, Clinical -- Periodicals
615.1 - Journal URLs:
- http://jcp.sagepub.com/ ↗
http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)1552-4604 ↗
http://onlinelibrary.wiley.com/ ↗
http://firstsearch.oclc.org ↗
http://firstsearch.oclc.org/journal=0091-2700;screen=info;ECOIP ↗ - DOI:
- 10.1002/jcph.514 ↗
- Languages:
- English
- ISSNs:
- 0091-2700
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 4958.680000
British Library DSC - BLDSS-3PM
British Library HMNTS - ELD Digital store - Ingest File:
- 3283.xml